Honest Comparison · June 2026
REMEVi vs. Hims/Hers
We compared pricing, features, bilingual support, and safety record across both platforms. Here's exactly what we found — no spin.
Side-by-side
REMEVi vs. Hims/Hers feature by feature
Based on publicly available data, pricing pages, and patient reviews — June 2026.
| Feature | REMEVi | Hims / Hers |
|---|---|---|
| GLP-1 pricing | ✅ $149 first month, then $279/mo ($199/mo on 52-wk plan) — all-in | ~$199/mo + possible lab/consult fees |
| Spanish language support | ✅ Fully bilingual (built-in) | ❌ English only |
| Price increases with dose | ✅ Never — no dose upcharge | ⚠️ Varies by plan |
| Data security | ✅ Zero incidents to date | ⚠️ Reported incidents |
| Hidden fees | ✅ None — all-inclusive | ⚠️ Lab fees, add-ons |
| Support response time | ✅ 2-hour response target (EN · ES) | ❌ 24–48 hours typical |
| LegitScript certified | ✅ Certified | ✅ Certified |
| Bilingual care coordinator | ✅ Assigned to every patient | ❌ Not offered |
Pricing and features subject to change. Always verify current pricing on each provider's website.
The bilingual difference
Built bilingual — not retrofitted
Hims/Hers operates exclusively in English. REMEVi was built bilingual from the ground up. Every intake form, provider note, care coordinator message, and patient touchpoint is available in fluent English and Spanish.
GLP-1 programs
How the GLP-1 programs compare
Both REMEVi and Hims/Hers offer compounded semaglutide and tirzepatide for weight loss. The active pharmaceutical ingredients are the same — what differs is the experience around the medication: pricing structure, care team access, language support, and response time.
On pricing: REMEVi's semaglutide is $149 for your first month ($130 welcome discount applied automatically at checkout), then $279/month month-to-month — or $199/month on the 52-week plan — all-inclusive. Hims typically prices GLP-1 plans at approximately $199/month and may charge separately for lab work or quarterly consultations. Always verify current pricing directly on each provider's site, as telehealth pricing changes frequently.
On support: REMEVi assigns every patient a dedicated bilingual care coordinator with a 2-hour response target. Hims/Hers operates primarily through asynchronous messaging with no guaranteed response time. For patients managing side effects, dosage questions, or medication concerns, response time matters significantly.
On clinical oversight: Both platforms use licensed US providers for prescribing. REMEVi licensed providers are licensed in the patient's specific state. Prescription approval typically occurs within 24 hours on both platforms.
On language: This is where the platforms diverge completely. Hims/Hers operates exclusively in English. REMEVi's entire platform — intake forms, clinical summaries, medication instructions, care coordinator communications — is available natively in English and Spanish. For the 62 million Spanish-speaking Americans, this is not a minor feature. It is a fundamental difference in the quality of care they receive.
FAQ
Common questions
It depends on the plan you compare. REMEVi's semaglutide is $149 for your first month ($130 welcome discount applied automatically at checkout), then $279/month month-to-month — or $199/month on a 52-week prepay plan. That price is all-inclusive: clinical review, medication, shipping, and support. Hims advertises GLP-1 plans from a similar monthly price, but may charge additional fees for labs or consultations. Compare the all-in number for your situation, not the headline.
Hims/Hers currently offers services in English only. REMEVi is the only telehealth platform in the US built natively bilingual — every intake form, care coordinator, and patient message is available in English and Spanish from day one.
Hers (the sister brand) offers a range of women's health services. REMEVi today focuses on doing one thing exceptionally well: bilingual GLP-1 weight loss care for women and men. Dedicated women's health programs are on our roadmap for later in 2026.
Both offer compounded semaglutide. REMEVi differentiates with transparent all-in pricing, bilingual support, and a 2-hour response target. For Spanish-speaking patients, REMEVi is the clear choice.
Yes. Switching is straightforward — complete REMEVi's 5-minute intake form, a clinician reviews your case within 24 hours, and your medication ships within days. You do not need to formally cancel Hims before starting with REMEVi. Simply time your transition to avoid overlapping charges.
Both REMEVi and Hims offer compounded semaglutide and compounded tirzepatide prescribed by licensed US providers and prepared by state-licensed compounding pharmacies. Compounded medications are non-FDA-approved preparations and are not generic versions of, nor the same as, Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. REMEVi differs from Hims on bilingual support, response time, and pricing transparency.
Both platforms have licensed providers available to address side effect concerns. REMEVi's 2-hour response target from a bilingual care coordinator means you get faster human support when managing nausea, fatigue, or dosage concerns — common in the first weeks of GLP-1 therapy.
Compare REMEVi with other GLP-1 providers
See how REMEVi stacks up on price, bilingual support, and transparency.
Ready to get started with REMEVi?
Clinical review in 24 hours. No insurance needed. $149 for your first month, then $279/mo ($199/mo on 52-week plan), all-inclusive.
See if you qualify